Pulmonary Stents Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Pulmonary stents, also referred to as airway or lung stents, are implantable devices, typically constructed from medical-grade metals or polymers, designed to maintain patency in narrowed, compressed, or malacic airways within the tracheobronchial tree. They are used to treat conditions such as tracheobronchomalacia, benign and malignant airway strictures, and complications arising from chronic obstructive pulmonary disease (COPD), asthma, and certain infections. The broader global stents market generated revenues of approximately $14.8 billion in 2024 and is projected to approach $21.1 billion by 2034 at a CAGR of 3.6%, with the pulmonary stents segment representing a significant and steadily growing portion. The pulmonary stents segment specifically is valued at approximately $8.528 billion in 2026, expanding at roughly 4.0% annually, a pace consistent with, and slightly above, the overall stents market trajectory.

• •The global stents market was valued at approximately $14.8 billion in 2024 and is projected to reach $21.1 billion by 2034 (CAGR 3.6%).
• •The pulmonary/airway stents segment is valued at approximately $8.528 billion in 2026, growing at approximately 4.0% per year.
• •Pulmonary stents treat airway obstructions caused by COPD, asthma, tracheobronchomalacia, and malignant or benign strictures.

Rising global prevalence of chronic respiratory diseases, driven by persistent air pollution, tobacco use, aging demographics, and increased clinical diagnosis, is the primary catalyst for demand in the pulmonary stents market. The expanding elderly population is a significant contributor, as older adults face disproportionately high rates of COPD, interstitial lung disease, and airway structural deterioration requiring interventional management. Improvements in bronchoscopic and endoscopic delivery technologies have broadened the pool of eligible patients by enabling less invasive placement and reducing procedural risk, which in turn supports higher adoption rates across hospitals and outpatient facilities. Continued investment in research and development of next-generation stent materials, including drug-eluting, bioabsorbable, and covered stent configurations, is expected to extend clinical utility and drive further market penetration over the medium to long term.

• •Rising global burden of COPD, asthma, and other chronic respiratory diseases, compounded by aging demographics, is the primary demand driver.
• •Advances in minimally invasive bronchoscopic delivery and imaging guidance have expanded the treatable patient population.
• •Ongoing R&D into drug-eluting, bioabsorbable, and covered stent technologies is broadening clinical indications and improving patient outcomes.

The pulmonary stents market is commonly segmented by stent type, material, application, and end-user. By material, the market is broadly divided into metallic stents, including stainless steel, nitinol (shape-memory alloy), and cobalt-chromium, and polymeric stents, with metallic variants dominating due to superior radial strength and proven long-term performance, while biodegradable polymers represent a growing innovation niche. Applications span benign airway conditions such as tracheobronchomalacia and post-intubation strictures, as well as malignant airway obstruction from lung cancer, with cancer-related indications gaining share as interventional pulmonology advances. North America currently leads the market, supported by advanced healthcare infrastructure, high procedure volumes, and early adoption of novel stent technologies, while Europe and Asia-Pacific represent significant and accelerating markets driven by large patient populations and expanding access to interventional respiratory care.

• •Metallic stents (nitinol and cobalt-chromium) currently dominate the segment, with biodegradable polymeric stents emerging as a high-growth niche.
• •Applications are divided between benign airway conditions and malignant obstruction, with oncology-related airway stenting representing an expanding area.
• •North America holds the leading regional position, with Europe and Asia-Pacific as the next-largest and fastest-growing markets.

Who are the notable companies in the industry?

The pulmonary stents market exhibits a moderately consolidated to semi-fragmented competitive structure, with the segment embedded within the much broader cardiovascular and vascular device industry where several large diversified medical technology firms maintain stent product portfolios. The market features a mix of fully integrated manufacturers, firms that control design, manufacturing, and global distribution, alongside more focused specialty producers that concentrate on respiratory-specific stent technologies and airway intervention systems. Competition is shaped substantially by technology and process route: nitinol-based self-expanding stents dominate the metallic segment, while extrusion and molding processes underpin polymeric stent production, with silicone and polyurethane materials prominent in silicone stent lines. Regional manufacturing and distribution concentration is centered in North America and Western Europe, where regulatory pathways for medical device approval are most established, though production and R&D activity in Asia-Pacific is rising in response to growing domestic demand and favorable manufacturing economics.

• •The market is moderately consolidated, with the segment embedded within the broader cardiovascular stent industry dominated by large diversified medical technology firms.
• •Product technology routes include nitinol self-expanding metallic stents and silicone/polymeric molded stents, with competing process routes reflecting distinct material science and regulatory profiles.
• •Regional manufacturing and regulatory capacity is concentrated in North America and Western Europe, with Asia-Pacific capacity expanding.

What are the recent trends and outlook?

Looking ahead, the pulmonary stents market is expected to maintain a steady growth trajectory, with the segment on track to continue expanding at approximately 4.0% annually. Key trends include increasing adoption of bioabsorbable and drug-eluting stent technologies aimed at reducing long-term complications such as granulation tissue formation and restenosis, which have historically limited durable clinical outcomes. Personalized airway stenting, guided by advanced imaging, 3D-printed airway models, and customized stent sizing, represents an emerging clinical direction with the potential to improve procedural precision and patient-specific outcomes. The continued expansion of interventional pulmonology as a distinct subspecialty, alongside growing investment in clinical trials focused on airway device safety and efficacy, is likely to support steady market growth and broaden the scope of approved indications through the early 2030s.

• •Bioabsorbable and drug-eluting pulmonary stents are expected to gain market share by reducing chronic complications such as restenosis and granulation tissue overgrowth.
• •Personalized stenting approaches leveraging 3D modeling and advanced imaging are emerging as a high-value clinical direction.
• •Growth of interventional pulmonology as a subspecialty and expanding clinical trial activity will support market expansion and new indications through the early 2030s.